Israel · Delayed Price · Currency is ILS · Price in ILA InterCure Statistics
Total Valuation
InterCure has a market cap or net worth of ILS 160.98 million. The enterprise value is 297.16 million.
| Market Cap | 160.98M |
| Enterprise Value | 297.16M |
Important Dates
The last earnings date was Friday, May 15, 2026.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
InterCure has 54.68 million shares outstanding. The number of shares has increased by 17.17% in one year.
| Current Share Class | 54.68M |
| Shares Outstanding | 54.68M |
| Shares Change (YoY) | +17.17% |
| Shares Change (QoQ) | -10.76% |
| Owned by Insiders (%) | 26.19% |
| Owned by Institutions (%) | 3.13% |
| Float | 37.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.60 |
| PB Ratio | 0.41 |
| P/TBV Ratio | 0.91 |
| P/FCF Ratio | 12.11 |
| P/OCF Ratio | 9.56 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.32 |
| EV / Sales | 1.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 22.36 |
Financial Position
The company has a current ratio of 1.48, with a Debt / Equity ratio of 0.46.
| Current Ratio | 1.48 |
| Quick Ratio | 0.91 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | n/a |
| Debt / FCF | 13.77 |
| Interest Coverage | -3.42 |
Financial Efficiency
Return on equity (ROE) is -9.27% and return on invested capital (ROIC) is -12.62%.
| Return on Equity (ROE) | -9.27% |
| Return on Assets (ROA) | -5.78% |
| Return on Invested Capital (ROIC) | -12.62% |
| Return on Capital Employed (ROCE) | -14.12% |
| Weighted Average Cost of Capital (WACC) | 7.97% |
| Revenue Per Employee | 948,070 |
| Profits Per Employee | -125,298 |
| Employee Count | 285 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 2.01 |
Taxes
| Income Tax | -7.32M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.59% in the last 52 weeks. The beta is 0.57, so InterCure's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | -44.59% |
| 50-Day Moving Average | 256.94 |
| 200-Day Moving Average | 373.70 |
| Relative Strength Index (RSI) | 55.59 |
| Average Volume (20 Days) | 58,341 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InterCure had revenue of ILS 270.20 million and -35.71 million in losses. Loss per share was -0.66.
| Revenue | 270.20M |
| Gross Profit | 40.70M |
| Operating Income | -67.24M |
| Pretax Income | -44.10M |
| Net Income | -35.71M |
| EBITDA | -55.34M |
| EBIT | -67.24M |
| Loss Per Share | -0.66 |
Balance Sheet
The company has 46.68 million in cash and 183.01 million in debt, with a net cash position of -136.34 million or -2.49 per share.
| Cash & Cash Equivalents | 46.68M |
| Total Debt | 183.01M |
| Net Cash | -136.34M |
| Net Cash Per Share | -2.49 |
| Equity (Book Value) | 396.36M |
| Book Value Per Share | 7.25 |
| Working Capital | 102.38M |
Cash Flow
In the last 12 months, operating cash flow was 16.84 million and capital expenditures -3.55 million, giving a free cash flow of 13.29 million.
| Operating Cash Flow | 16.84M |
| Capital Expenditures | -3.55M |
| Depreciation & Amortization | 11.90M |
| Net Borrowing | -29.13M |
| Free Cash Flow | 13.29M |
| FCF Per Share | 0.24 |
Margins
Gross margin is 15.06%, with operating and profit margins of -24.89% and -13.22%.
| Gross Margin | 15.06% |
| Operating Margin | -24.89% |
| Pretax Margin | -16.32% |
| Profit Margin | -13.22% |
| EBITDA Margin | -20.48% |
| EBIT Margin | -24.89% |
| FCF Margin | 4.92% |
Dividends & Yields
InterCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.17% |
| Shareholder Yield | -17.17% |
| Earnings Yield | -22.18% |
| FCF Yield | 8.26% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 8, 2021. It was a reverse split with a ratio of 0.2247564764.
| Last Split Date | Apr 8, 2021 |
| Split Type | Reverse |
| Split Ratio | 0.2247564764 |
Scores
InterCure has an Altman Z-Score of 0.15 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.15 |
| Piotroski F-Score | 4 |